Stock comparison
Alphatec Holdings
Royalty Pharma
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ATEC
Alphatec Holdings
Market cap
$1.27B
Sector
Healthcare
RPRX
Royalty Pharma
Market cap
$23.44B
Sector
Healthcare
Overall winner
Royalty Pharma RPRX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ATEC | RPRX | Winner |
|---|---|---|---|
| Warren Buffett | 26F | 66C | RPRX |
| Benjamin Graham | 65D | 84A | RPRX |
| Philip Fisher | 50C | 65C | RPRX |
| Peter Lynch | 71C | 60C | ATEC |
| Joel Greenblatt | 0F | 40D | RPRX |
| Charlie Munger | 37D | 68D | RPRX |
| Terry Smith | 33F | 58D | RPRX |
Side-by-side metrics
| Metric | ATEC | RPRX |
|---|---|---|
| Market cap | $1.27B | $23.44B |
| P/E (TTM) | - | 27.6x |
| EV/EBIT | - | 19.9x |
| ROIC (TTM) | -8.94% | 8.43% |
| Gross margin | 65.32% | 99.95% |
| Net margin | -15.93% | 33.91% |
| Revenue CAGR 5y | 33.14% | 0.96% |
| EPS CAGR 5y | - | 11.83% |
| Debt / Equity | 33.0x | 1.3x |
| Dividend yield | 0.0% | 1.72% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ATEC leads on
- EV/EBIT-vs 19.9x+199%
- P/E (TTM)-vs 27.6x+135%
- Revenue CAGR 5y33.14%vs 0.96%+97%
RPRX leads on
- ROIC (TTM)8.43%vs -8.94%+194%
- Net margin33.91%vs -15.93%+147%
- Dividend yield1.72%vs 0.0%+100%
- Debt / Equity1.3xvs 33.0x+96%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.